Fencamfamine

Fencamfamine

Clinical data
ATC code	N06BA06 (WHO)
Identifiers
IUPAC name N-ethyl-3-phenyl-norbornan-2-amine
CAS Number	2240-14-4
PubChem CID	14584
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C15H21N
Molar mass	215.34 g·mol−1

WikiDoc Resources for Fencamfamine
Articles
Most recent articles on Fencamfamine Most cited articles on Fencamfamine Review articles on Fencamfamine Articles on Fencamfamine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Fencamfamine Images of Fencamfamine Photos of Fencamfamine Podcasts & MP3s on Fencamfamine Videos on Fencamfamine
Evidence Based Medicine
Cochrane Collaboration on Fencamfamine Bandolier on Fencamfamine TRIP on Fencamfamine
Clinical Trials
Ongoing Trials on Fencamfamine at Clinical Trials.gov Trial results on Fencamfamine Clinical Trials on Fencamfamine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Fencamfamine NICE Guidance on Fencamfamine NHS PRODIGY Guidance FDA on Fencamfamine CDC on Fencamfamine
Books
Books on Fencamfamine
News
Fencamfamine in the news Be alerted to news on Fencamfamine News trends on Fencamfamine
Commentary
Blogs on Fencamfamine
Definitions
Definitions of Fencamfamine
Patient Resources / Community
Patient resources on Fencamfamine Discussion groups on Fencamfamine Patient Handouts on Fencamfamine Directions to Hospitals Treating Fencamfamine Risk calculators and risk factors for Fencamfamine
Healthcare Provider Resources
Symptoms of Fencamfamine Causes & Risk Factors for Fencamfamine Diagnostic studies for Fencamfamine Treatment of Fencamfamine
Continuing Medical Education (CME)
CME Programs on Fencamfamine
International
Fencamfamine en Espanol Fencamfamine en Francais
Business
Fencamfamine in the Marketplace Patents on Fencamfamine
Experimental / Informatics
List of terms related to Fencamfamine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Fencamfamine (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. Reactivan is still rarely used for treating depressive day-time fatigue, lack of concentration and lethargy, particularly in individuals who have chronic medical conditions, as its favourable safety profile makes it the most suitable drug in some cases.

Legal Status: Schedule IV (USA)

Pharmacology

Fencamfamine acts as an indirect dopamine agonist. It releases dopamine by a similar mechanism to amphetamines, but is 10x less potent than dexamphetamine at producing this effect. The main mechanism of action is instead inhibition of dopamine reuptake, more similar to that of methylphenidate. Also unlike amphetamines, fencamfamine does not inhibit the action of monoamine oxidase enzymes and so is somewhat safer. Some experiments also suggest a role for opioid receptors in the activity of fencamfamine, as low doses can cause paradoxical sedation, and some effects of the drug are blocked by naloxone.

Side effects

Side effects include: dry mouth, loss of appetite, restlessness and tremor.

Contraindications

Contraindications: should not be used in patients with heart disease, angina, glaucoma, thyrotoxicosis or in patients being treated with monoamine oxidase inhibitors.